Core Insights - The Beauty Health Company reported Q3 2025 financial results, highlighting disciplined execution and operational efficiency, with revenue of $70.7 million and Adjusted EBITDA of $8.9 million, exceeding guidance [2][6][10] Financial Performance - Q3 2025 net sales were $70.7 million, a decrease of 10.3% compared to Q3 2024, attributed to lower delivery systems and consumables sales [6][10] - Gross profit for Q3 2025 was $45.6 million, with a gross margin of 64.6%, up from 51.6% in Q3 2024, primarily due to lower inventory charges and a favorable shift towards consumables [6][10] - Adjusted EBITDA increased to $8.9 million in Q3 2025 from $8.1 million in Q3 2024, driven by lower operational spending [10][30] Operational Metrics - Total delivery systems sold in Q3 2025 were 875, down from 1,118 in Q3 2024, reflecting a challenging macroeconomic environment [10][12] - The active install base reached 35,409 as of September 30, 2025, compared to 34,162 in the prior year [3][10] Regional Sales Breakdown - In Q3 2025, delivery systems net sales were $20.8 million, with regional contributions as follows: - Americas: $13.6 million - Asia-Pacific: $2.1 million - EMEA: $5.1 million [9][10] - Consumables net sales totaled $49.8 million, with regional contributions: - Americas: $34.7 million - Asia-Pacific: $4.2 million - EMEA: $10.9 million [9][10] Balance Sheet and Cash Flow - As of September 30, 2025, cash, cash equivalents, and restricted cash were approximately $219 million, down from $370 million at the end of 2024, mainly due to the repurchase of convertible senior notes [10][22] - The company reported a net loss of $11.0 million in Q3 2025, an improvement from a net loss of $18.3 million in Q3 2024, attributed to lower operational spending and higher gross margin [6][10] Updated Financial Guidance - The company updated its 2025 financial guidance, projecting net sales between $293 million and $300 million and Adjusted EBITDA between $37 million and $39 million [8][11]
BeautyHealth Reports Third Quarter 2025 Financial Results